Nicotinamide as an Early Alzheimer's Disease Treatment

Mild Cognitive Impairment Clinical Trial

— NEAT  

Official title:

A Double-Blind-Randomized, Placebo-Controlled Adaptive Design Trial of Nicotinamide in Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Dementia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03061474
• Other study ID #: 20163246
• Status: Completed
• Phase: Phase 2
• Start date: July 12, 2017
• Est. completion date: August 30, 2022

Study information

• Verified date: September 2023
• Source: University of California, Irvine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to test whether nicotinamide, also known as vitamin B3 or niacinamide, taken in high doses, can reduce phosphorylation of tau (the protein that accumulates in neurofibrillary tangles) in people with Mild Cognitive Impairment or mild Alzheimer's disease (AD) dementia.

Description:

Nicotinamide, the amide of nicotinic acid (vitamin B3/niacin), is an oral therapy with a wealth of clinical data in a variety of therapeutic areas, including preliminary data supporting its safety in Alzheimer's disease (AD). Preclinical work in a mouse model that develops both plaques and tangles supports the hypothesis that nicotinamide can act as a histone deacetylase (HDAC) inhibitor to reduce phosphorylation of tau.

The study will implement a group sequential design, incorporating a futility analysis with a go/no-go decision conditional on cerebral spinal fluid CSF biomarker outcomes at 12-months. The primary outcome for the trial is change in p-tau231.

This study timeline includes a screening phase of up to 60 days and treatment phase which is expected to last about 48 weeks and will include 4 study visits.

An additional 12-month treatment and follow-up period is planned, contingent upon a "go" decision based on the primary outcome (CSF p-tau231) or one planned secondary outcome (CSF p-tau181)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: August 30, 2022
• Est. primary completion date: August 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

1. Mild Cognitive Impairment (MCI) or dementia due to Alzheimer's disease (AD)

2. Biomarker criteria:

Cerebral Spinal Fluid (CSF) Amyloid Beta 1-42 (Aß42) <= 600 pg/mL, or A ratio of total tau to Aß42 = 0.39.

3. Mini-Mental State Exam (MMSE) = 20

4. Blood laboratories, urinalysis, and electrocardiogram are within normal limits or deemed clinically not significant by the site investigator

5. Stable medications (including approved AD therapies) for at least 4 weeks

6. At least 6 years of education

7. Able to swallow oral tablets

8. Speaks English fluently

9. Available qualified study partner (=3 times per week in-person communication with the participant)

Exclusion Criteria:

1. Active neurological or psychiatric diagnosis other than AD that may affect cognition and/or function. (Obstructive sleep apnea is permitted, if treated.)

2. Inability to undergo lumbar puncture, including use of Coumadin, novel oral anticoagulants, clopidogrel, or dipyridamole. Use of aspirin <= 325mg daily is permitted.

3. Hachinski ischemic scale > 4

4. Magnetic Resonance Imaging (MRI) incompatibility

5. MRI evidence of cortical stroke >1cm, superficial siderosis, or extensive white matter hyperintensity (Cardiovascular Health Study score 7-8+)

6. Diagnosis of cancer in the previous 5 years (with the exception of basal or squamous cell carcinoma)

7. Geriatric Depression Scale (GDS) score >6

8. History within the past 5 years of alcohol or substance use disorder

9. Laboratory evidence of a clinically significant abnormality that may interfere with study assessments

10. Active partial or total malabsorptive disease (e.g., celiac disease)

11. Resides in a skilled nursing facility

12. Participation in a clinical trial of a potential disease-modifying therapy for AD in previous 6-months (time between last investigational drug administration and baseline for the current study)

13. Pregnant, lactating or of child bearing potential (that is, women must be 2 years post-menopausal or surgically sterile to be considered not child bearing potential).

14. Unwillingness to abstain from over-the-counter nicotinamide for the duration of the trial

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease
• Cognitive Dysfunction
• Mild Cognitive Impairment

Intervention

Drug:
• Nicotinamide
Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.
• Placebo Comparator
Oral Tablet

Locations

Country	Name	City	State
United States	University of California, Irvine	Irvine	California
United States	University of California, Los Angeles	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, Irvine

Country where clinical trial is conducted

United States, 

References & Publications (2)

Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, LaFerla FM. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci. 2008 Nov 5;28(45):11500-10. doi: 10.1523/JNEUROSCI.3203-08.2008. — View Citation

Liu D, Pitta M, Jiang H, Lee JH, Zhang G, Chen X, Kawamoto EM, Mattson MP. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession. Neurobiol Aging. 2013 Jun;34(6):1564-80. doi: 10.1016/j.neurobiolaging.2012.11.020. Epub 2012 Dec 25. Erratum In: Neurobiol Aging. 2013 Sep;34(9):e3. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in P-tau 231	Change in key peptide in cerebrospinal fluid (CSF) from baseline to 48 weeks. Higher phosphorylated tau (p-tau) is associated with a severity of Alzheimer's disease pathology.	Baseline to 48 weeks
Primary	Vital Signs - Weight	Weight in kg was recorded at every study visit (screening, baseline, week 12, week 24, and week 48)	Screening through end of study (week 48)
Primary	Vital Signs - BMI	Body Mass Index (BMI) was recorded at every study visit (screening, baseline, week 12, week 24, and week 48)	Screening through end of study (week 48)
Primary	Vital Signs - Systolic Blood Pressure	Systolic blood pressure was recorded at every study visit (screening, baseline, week 12, week 24, and week 48)	Screening through end of study (week 48)
Primary	Vital Signs - Diastolic Blood Pressure	Diastolic blood pressure was recorded at every study visit (screening, baseline, week 12, week 24, and week 48)	Screening through end of study (week 48)
Primary	Vital Signs - Pulse	Pulse rate was recorded at every study visit (screening, baseline, week 12, week 24, and week 48)	Screening through end of study (week 48)
Primary	Count of Treatment Emergent Adverse Events	Count of treatment emergent adverse events (TEAEs) over the duration of the study period (baseline to 48 weeks).	Baseline to 48 weeks
Primary	Count of Adverse Events by Severity	Count of treatment emergent adverse events (TEAEs) over the duration of the study period (baseline to 48 weeks).	Baseline to 48 weeks
Primary	Columbia-Suicide Severity Rating Scale	The Columbia-Suicide Severity Rating Scale (C-SSRS) captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the corresponding assessment period. The scale includes suggested questions to elicit the type of information needed to determine if a suicide-related thought or behavior occurred. The number and proportion of subjects with treatment emergent Suicidal ideation or behavior during the study period of (baseline to week 48) will be reported overall and by study arm. Treatment emergent suicidal ideation or behavior is defined as a "yes" answer at any time during treatment to any one of the questions in the ten suicidal ideation and behavior categories (Categories 1- 10) on the C-SSRS. Self-injurious behavior without suicidal intent, while assessed on the C-SSRS, does not form part of this outcome.	Baseline to 48 weeks
Primary	ECG Abnormalities	Count of participants experiencing at least one electrocardiogram (ECG) abnormality.	Baseline to 48 weeks
Primary	QTC Abnormalities	Count of participants experiencing at least one electrocardiogram (ECG) QT interval abnormality. Abnormal defined as above 460 for men and above 470 for women.	Baseline to 48 weeks
Primary	Change in QTC	Average within-subject change in electrocardiogram QT interval.	Baseline to 48 weeks
Secondary	Change in ab40	Change in key peptide in cerebrospinal fluid (CSF) from baseline to 48 weeks. Lower ab40 is associated with a greater probability of fibrillar amyloid burden in the brain.	Baseline to 48 weeks
Secondary	Change in ab42	Change in key peptide in cerebrospinal fluid (CSF) from baseline to 48 weeks. Lower ab42 is associated with a greater probability of fibrillar amyloid burden in the brain.	Baseline to 48 weeks
Secondary	Change in P-tau 181	Change in key peptide in cerebrospinal fluid (CSF) from baseline to 48 weeks. Higher total value is associated with greater severity of Alzheimer's disease pathology.	Baseline to 48 weeks
Secondary	Change in Total Tau	Change in CSF total tau in individuals with mild Alzheimer's disease (AD) dementia or Mild Cognitive Impairment due to AD.	Baseline to 48 weeks
Secondary	Change in Ratio of Total Tau/ab40	Change in ratio of key peptides in cerebrospinal fluid (CSF) from baseline to 48 weeks. A lower ab40/tau ratio is associated with a higher risk of dementia.	Baseline to 48 weeks
Secondary	Change in Ratio of Total Tau/ab42	Change in ratio of key peptides in cerebrospinal fluid (CSF) from baseline to 48 weeks. A lower ab42/tau ratio is associated with a higher risk of dementia.	Baseline to 48 weeks
Secondary	ADASCog-13	ADAS-Cog13 is a structured scale that evaluates memory (immediate and delayed word recall; immediate word recognition), receptive and expressive language, orientation, ideational praxis (preparing a letter for mailing), constructional praxis (copying figures), and attention (number cancellation). Ratings of spoken language, language comprehension, word finding difficulty, and ability to remember test instructions also are obtained. Range: 0-85; higher scores indicate greater impairment.	Baseline to 48 weeks
Secondary	Activities of Daily Living - Mild Cognitive Impairment	The ADCS-ADL-MCI is a measure of patient functional performance in Alzheimer's Disease and Mild Cognitive Impairment trials. The informant-based questionnaire assesses conduct of basic and instrumental Activities of Daily Living (ADLs). A total of 24 ADLs are evaluated. Scores range from 0 to 53, with higher scores representing more maintained function.	Baseline to 48 weeks
Secondary	CDR Sum of Boxes	CDR-SB is a composite rating of cognition and everyday function which incorporates both informant input and direct assessment of performance. It assesses through semi-structured interview three cognitive domains (memory, orientation, and judgement/problem solving) and three everyday functional domains (community affairs, home and hobbies, personal care). Level of impairment in each of the six domains is rated from none (score=0) to severe (score=3). The six domain scores are then summed to create the CDR-SB. Range 0-18; higher scores indicate greater impairment.	Baseline to 48 weeks